June 2015
Volume 56, Issue 7
Free
ARVO Annual Meeting Abstract  |   June 2015
Quantitative OCT Subanalysis of Eyes with Choroidal Neovascularization Switched from Multiple Injections of Bevacizumab or Ranibizumab to Intravitreal Aflibercept
Author Affiliations & Notes
  • Amirhossein Hariri
    Doheny Eye Institute - UCLA, Los Angeles, CA
  • Bruno Diniz
    Doheny Eye Institute - UCLA, Los Angeles, CA
  • Lyndsey Fou
    Doheny Eye Institute - UCLA, Los Angeles, CA
  • Linda Anne Lam
    USC Eye Institute, Los Angeles, CA
  • Muneeswar Gupta Nittala
    Doheny Eye Institute - UCLA, Los Angeles, CA
  • Srinivas R Sadda
    Doheny Eye Institute - UCLA, Los Angeles, CA
  • Footnotes
    Commercial Relationships Amirhossein Hariri, None; Bruno Diniz, None; Lyndsey Fou, None; Linda Lam, None; Muneeswar Nittala, None; Srinivas Sadda, Alcon (C), Alcon (C), Allergan (C), Allergan (C), Allergan (F), Allergan (F), Allergan (R), Allergan (R), Carl Zeiss Meditec (C), Carl Zeiss Meditec (C), Carl Zeiss Meditec (F), Carl Zeiss Meditec (F), Carl Zeiss Meditec (R), Carl Zeiss Meditec (R), Genentech (C), Genentech (C), Genentech (F), Genentech (F), Novartis (C), Novartis (C), Optos (C), Optos (C), Optos (F), Optos (F), Optos (R), Optos (R), Roche (C), Roche (C)
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2015, Vol.56, 4591. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Amirhossein Hariri, Bruno Diniz, Lyndsey Fou, Linda Anne Lam, Muneeswar Gupta Nittala, Srinivas R Sadda; Quantitative OCT Subanalysis of Eyes with Choroidal Neovascularization Switched from Multiple Injections of Bevacizumab or Ranibizumab to Intravitreal Aflibercept. Invest. Ophthalmol. Vis. Sci. 2015;56(7 ):4591.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: To assess the therapeutic response after switching from multiple injections of bevacizumab or ranibizumab to aflibercept in the eyes with neovascular age-related macular degeneration (AMD).

Methods: Thirty-one eyes of 31 patients with neovascular AMD were collected retrospectively in this IRB approved study. To be included in the analysis, subjects were required to have been deemed as suboptimal responders by the treating physician despite multiple injections of bevacizumab or ranibizumab, and as a result, were switched to aflibercept therapy. Suboptimal response was defined as the presence of at least some intraretinal, subretinal, or sub- retinal pigment epithelial (RPE) fluid 4-6 weeks after therapy despite multiple monthly (>3) injections. Volume spectral domain optical coherence tomography (SD OCT) scans that were taken on the last visit just prior to switching therapies (within 4-6 weeks of the switch), at the time of the switch, at least 4 weeks after switching , and after three aflibercept injections were exported and analyzed using validated reading center OCT grading software (known as OCTOR). Following segmentation, the volumes of the neurosensory retina, subretinal fluid (SRF), and pigment epithelial detachment (PED) were computed and compared at the various time points. In addition, mean ETDRS visual acuity of the patients at those visits were compared.

Results: After the last injection of bevacizumab or ranibizumab neurosensory retinal volume increased by 0.10 ± 0.56 mm3, SRF volume by 0.07 ± 0.29 mm3, and PED volume by 0.19 ± 0.49 mm3 ; but following switching to aflibercept, a decrease of 0.32 ± 0.4 mm3 in neurosensory retinal volume, 0.13 ± 0.32 mm3 in SRF volume, and 0.67 ± 0.89 mm3 in PED volume was observed; all these decreases were statistically significant (p=0.01, 0.04, and 0.001, respectively). While the mean ETDRS visual acuity after the last injection of bevacizumab or ranibizumab was decreased from 65.3 ± 12.3 to 64.5 ± 14, it was increased to 68.3 ± 10.8 after switching (p=0.04).These favorable outcomes were sustained after three monthly injections of aflibercept.

Conclusions: Switching to aflibercept therapy in eyes with persistent fluid after multiple intravitreal injections of bevacizumab or ranibizumab was associated with an early reduction in all fluid compartments and improvement in visual acuity.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×